Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/SHA-384/273B59832B57712885E81C4185B30D5C646DBAC1D0B6648B90DA18FA7F48048C3CED89B2CB38947BF76BEF44462B7C13http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/273B59832B57712885E81C4185B30D5C646DBAC1D0B6648B90DA18FA7F48048C3CED89B2CB38947BF76BEF44462B7C13http://www.w3.org/2000/01/rdf-schema#comment"In cisplatin-resistant ovarian cancer cells c-Myc enhances the expression of EZH2 by directly suppressing miR-137 that targets EZH2 mRNA. Inhibition of c-Myc-miR-137-EZH2 pathway re-sensitizes resistant cells to cisplatin. Clinical studies further confirm the activated c-Myc-miR-137-EZH2 pathway in platinum drug-resistant or recurrent ovarian cancer patients."xsd:string
http://purl.uniprot.org/uniprot/#_76DCECDE1B5C8CA9662E587D824C7543F2A6667585961818357FE25B26BD4B6CF92B239D8C5514D37F0BB662837DD09Chttp://www.w3.org/1999/02/22-rdf-syntax-ns#subjecthttp://purl.uniprot.org/SHA-384/273B59832B57712885E81C4185B30D5C646DBAC1D0B6648B90DA18FA7F48048C3CED89B2CB38947BF76BEF44462B7C13
http://purl.uniprot.org/uniprot/B3CJ71http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/273B59832B57712885E81C4185B30D5C646DBAC1D0B6648B90DA18FA7F48048C3CED89B2CB38947BF76BEF44462B7C13
http://purl.uniprot.org/uniprot/#_B3CJ71-mappedCitation-30166592http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/273B59832B57712885E81C4185B30D5C646DBAC1D0B6648B90DA18FA7F48048C3CED89B2CB38947BF76BEF44462B7C13